Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors

Biosimilars: what clinicians should know

(2012) M. Weise et al.   BLOOD

Clinical safety of biosimilar recombinant human erythropoietins

(2012) Ivo Abraham et al.   Expert Opinion On Drug Safety

Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF

(2012) Nello Salesi et al.   Future Oncology

A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre

(2012) Karl Verpoort et al.   Therapeutic Advances in Medical Oncology

First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factor

(2011) François Lefrère et al.   ADVANCES IN THERAPY

Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments

(2011) Pere Gascón et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Plerixafor and Filgrastim XM02 (Tevagastrim®) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation

(2011) Giovanna Andreola et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers

(2011) H. Lubenau et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial

(2010) Cornelius F. Waller et al.   ANNALS OF HEMATOLOGY

Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial

(2010) Cornelius F. Waller et al.   ANNALS OF HEMATOLOGY

Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim

(2010) Pere Gascón et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer

(2010) Cornelius F. Waller et al.   Oncology Research and Treatment

Development of a new G-CSF product based on biosimilarity assessment

(2009) P. Gascon et al.   ANNALS OF ONCOLOGY

Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed Filgrastim Neupogen®

(2009) Heinz Lubenau et al.   BIODRUGS

XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

(2009) Ulrich Gatzemeier et al.   Journal of Thoracic Oncology

XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy

(2009) A. Engert et al.   LEUKEMIA & LYMPHOMA

Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin’s Lymphoma

(2009) Andreas Engert et al.   ONKOLOGIE

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

(2008) A del Giglio et al.   BMC CANCER